Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 6/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963407 | 0.83 | CYP1A2 (0.49) | CYP1A2CYP2C19CREBBPALDH1A1LMNA | |
| SCHEMBL16608745 | 0.77 | DNM2 (0.61) | TLR8CYP1A2CYP2C19ALDH1A1LMNA | |
| SCHEMBL14228432 | 0.76 | DNM2 (0.43) | TLR8CYP1A2ALDH1A1LMNAHTT | |
| SCHEMBL8585646 | 0.75 | TLR8 (0.81) | TLR8CYP1A2CYP2C19ALDH1A1LMNA | |
| SCHEMBL15585264 | 0.75 | TLR8 (0.51) | TLR8CYP1A2ALDH1A1LMNATP53 | |
| SCHEMBL28841507 | 0.75 | TLR8 (0.51) | TLR8CYP1A2ALDH1A1LMNATP53 | |
| SCHEMBL12963699 | 0.74 | NOS3 (0.55) | TLR8ALDH1A1LMNATP53TSHR | |
| SCHEMBL2629265 | 0.72 | POLB (0.43) | CYP1A2ALDH1A1LMNATSHRHTT | |
| SCHEMBL14459561 | 0.72 | PTGDR (0.55) | PTGDR | |
| SCHEMBL26877797 | 0.71 | TRPM8 (0.44) | CYP1A2CYP2C19CREBBPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | TLR8 1041/4885CYP1A2 273/4885CYP2C19 493/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | TLR8 1041/4885CYP1A2 273/4885CYP2C19 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.